Epix Pharmaceuticals, Inc.

European CHMP recommends granting marketing authorization for Vasovist

Published in Medical Imaging Business Week, July 28th, 2005

Epix Pharmaceuticals, Inc., (Epix) announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Schering AG's marketing authorization application for Vasovist (gadofosveset trisodium) for contrast-enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease.

The EU marketing application for MS-325, trade named Vasovist, was submitted in June 2004 by Schering AG, Epix' worldwide development and marketing partner. CHMP is the scientific committee of the European Medicines Agency (EMEA). The opinions of the CHMP generally serve as the basis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Imaging Business Week

Source: Medical Imaging Business Week (2005-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry